文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症病程中治疗与血细胞计数对生存及血管事件风险的回顾性分析

A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera.
PubMed 文献 · Br J Haematol · 2017-05-05

该回顾性研究纳入217例真性红细胞增多症患者,分析不同治疗下血细胞计数对并发症发生率和生存的影响。随访中78例(36%)发生至少一种并发症。羟基脲治疗者血管并发症(11%)少于仅放血治疗者(27%),且校正年龄、性别和诊断时期后生存更优。

要点

  • 羟基脲治疗者血管并发症发生率11%,低于仅放血治疗者的27%(P=0·013)。
  • 校正年龄、性别和诊断时期后,放血治疗者5年死亡风险为羟基脲治疗者的2·42倍(HR 2·42,95%CI 1·03-5·72,P=0·043)。
  • 羟基脲治疗者中每年需至少一次放血者与低放血需求者在生存和血管并发症方面无显著差异。

核心结论

  • 羟基脲治疗者血管并发症更少且校正后生存更优,羟基脲治疗者中为维持血细胞比容而补充放血是安全的。

研究设计与样本

  • 回顾性研究,纳入217例真性红细胞增多症患者,分析不同治疗下血细胞计数对并发症发生率和生存的影响。

主要发现

  • 随访期间78例(36%)患者发生至少一种并发症。
  • 诊断时年龄较大和乳酸脱氢酶升高为血管并发症的危险因素。
  • 发生血管并发症时,有并发症者中41%白细胞升高,无并发症者中20%白细胞升高(P=0·042)。
  • 羟基脲治疗者血管并发症发生率为11%,仅放血治疗者为27%(P=0·013)。
  • 校正年龄、性别和诊断时期后,放血治疗者相对于羟基脲治疗者5年风险比为2·42(95%CI 1·03-5·72,P=0·043)。

关键数值与推荐

  • 有并发症者中41%白细胞升高 vs 无并发症者中20%白细胞升高(P=0·042)。
  • 羟基脲治疗者血管并发症11% vs 仅放血治疗者27%(P=0·013)。
  • 放血治疗者相对于羟基脲治疗者5年风险比HR 2·42(95%CI 1·03-5·72,P=0·043)。

临床怎么用

  • 作者认为,羟基脲治疗者中为维持血细胞比容而补充放血是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vascular and non-vascular complications are common in patients with polycythaemia vera. This retrospective study of 217 patients with polycythaemia vera aimed to determine whether blood counts with respect to different treatments influenced the complication rate and survival. We found that 78 (36%) patients suffered from at least one complication during follow-up. Older age and elevated lactate dehydrogenase at diagnosis were found to be risk factors for vascular complications. When the vascular complication occurred, 41% of the patients with a complication had elevated white blood cells (WBC) compared with 20% of patients without a complication (P = 0·042). Patients treated with hydroxycarbamide (HC; also termed hydroxyurea) experienced significantly fewer vascular complications (11%) than patients treated with phlebotomy only (27%) (P = 0·013). We also found a survival advantage for patients treated with HC, when adjusted for age, gender and time period of diagnosis (Hazard ratio for phlebotomy-treated patients compared to HC-treated patients at 5 years was 2·42, 95% confidence interval 1·03-5·72, P = 0·043). Concerning survival and vascular complications, HC-treated patients who needed at least one phlebotomy per year were not significantly different from HC-treated patients with a low phlebotomy requirement. We conclude that complementary phlebotomy in HC-treated patients in order to maintain the haematocrit, is safe.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Enblom-Larsson A, Girodon F, Bak M, et al. A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. Br J Haematol. 2017. PMID: 28474342. doi:10.1111/bjh.14625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。